Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewEfaroxan hydrochloride
Discontinued Product
0792 has been discontinued.
View all Adrenergic α<sub>2</sub> Receptors products.
Description: α2 antagonist and I1, I3 ligand
Chemical Name: 2-(2-Ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1H-imidazole hydrochloride
Purity: ≥99% (HPLC)
Biological Activity for Efaroxan hydrochloride
Efaroxan hydrochloride is a potent, highly selective α2 adrenoceptor antagonist and imidazoline I1 receptor ligand (pKi values are 7.87, 7.42, 5.74, 7.28 and < 5 for α 2A, α2B, α2C, I1, and I2 receptors respectively). Promotes insulin secretion, at a site distinct from I1 or I2 (the putative I3 receptor) in vitro and in vivo.
Technical Data for Efaroxan hydrochloride
| M. Wt | 252.74 |
| Formula | C13H16N2O.HCl |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 89197-00-2 |
| PubChem ID | 11957548 |
| InChI Key | DWOIUCRHVWIHAH-UHFFFAOYSA-N |
| Smiles | Cl.CCC1(CC2=CC=CC=C2O1)C1=NCCN1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for Efaroxan hydrochloride
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for Efaroxan hydrochloride
References are publications that support the biological activity of the product.
Chapleo et al (1984) α-Adrenoceptor reagents 2. Effects of modification of the 1,4-benzodioxan ring system on α-adrenoceptor activity. J.Med.Chem. 27 570 PMID: 6143826
Eglen et al (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TiPS 19 381 PMID: 9786027
Mayer and Taberner (2002) Effects of the imidazoline ligands efaroxan and KU14R on blood glucose in the mouse. Eur.J.Pharmacol. 454 95 PMID: 12409010
Olmos et al (1994) Imidazolines stimulate release of Ins from RIN-5AH cells independently from imidazoline I1 and I2 receptors. Eur.J.Pharmacol. 262 41 PMID: 7813577
View Related Products by Target
View Related Products by Product Action
Keywords: Efaroxan hydrochloride, Efaroxan hydrochloride supplier, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, α2-Adrenergic, alpha2-Adrenergic, a2-adrenergic, antagonists, I1, I3, ligand, Receptors, General, Imidazolines, Adrenergic, Alpha-2, 0792, Tocris Bioscience
Citations for Efaroxan hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Efaroxan hydrochloride.
Reviews for Efaroxan hydrochloride
There are currently no reviews for this product. Be the first to review Efaroxan hydrochloride and earn rewards!
Have you used Efaroxan hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.